Assessment of Traditional Treatment Modality in the Management of Adenocarcinoma of Prostate: A Case Report Based on Cytokine Expression

Autor: S. Kaluthotage, N. Jayathilake, A.P.G. Amarasinghe, L.H.S. Umayangani, E.P.S. Chandana
Rok vydání: 2018
Předmět:
Zdroj: Journal of Global Oncology. 4:217s-217s
ISSN: 2378-9506
Popis: Background: Adenocarcinoma of prostate is one of the most common cancers in Sri Lanka. It is developed in the prostate gland which is in a male reproductive system. Aim: This clinical case report was conducted from September to November 2016 in the out patient department of Bandaranaike Memorial Ayurveda Research Institute (BMARI), Navinna, Sri Lanka to assess antitumor activity of the traditional treatment modality. Methods: A patient 65 years old who was attended with symptoms of competence of urination, flatulence, anorexia and diagnosed as adenocarcinoma of prostate with the evidence of early metastatic in 7th 8th ribs and L2 vertebra. Detailed history, clinical examinations and relevant investigations were conducted at BMARI and the Department of Zoology, Faculty of Science, University of Ruhuna, Sri Lanka. Five traditional herbal powder formulae namely C1 Choorna, KY Choorna, A1 Choorna, IM Choorna and SG Choorna were administered throughout period of study. Tumor marker expression and biochemical analysis were tested before and after treatments (after 45 days and 90 days of treatment). Further serum IL-2, IL-5, IFN-γ, PUMA were quantified using ELISA before and after the treatments (after 45 days and 90 days of treatment) as these cytokines play a significant role in tumor growth control. Results: Symptoms of adenocarcinoma of prostate were significantly improved and PSA was decreased. As the results of the ELISA, IL-2, IL-5, IFN-γ and PUMA concentrations were increased after the treatment. Conclusion: Expression level increased in all 4 cytokines over time indicating the possible control of adenocarcinoma of prostate growth by the 5 drug formulae. Further investigations are required to evaluate the efficacy of this drug modality in controlling adenocarcinoma of prostate.
Databáze: OpenAIRE